Pharmaceutical for Delaying Alzheimer’s Passes Clinical Trial

​The recipient of an MBA from the University of Kansas, Bradley DiTeresi is a financial service professional who pursues a wide range of hobbies and interests during his free time. Bradley DiTeresi maintains a strong community presence and is active in the Catholic Church. He is also known for his philanthropic endeavors, donating to organizations dedicated to Alzheimer's research and support, among other causes.

According to CBSNews.com, donanemab, a drug for stalling Alzheimer’s disease progression, has demonstrated its effectiveness in a 1,700-person clinical study by its manufacturer, Eli Lilly and Co. The Journal of the American Medical Association published the study, which shows that donanemab can stall Alzheimer’s by a few months. It also works better during the early stage of the disease.

As of July 2023, Eli Lilly is seeking US Food and Drug Administration approval for donanemab. If the FDA greenlights the drug, it would be the second it has approved for delaying Alzheimer’s disease.

Potentially disabling, Alzheimer’s is characterized by irreversible brain damage that erodes memory and cognitive function. As the disease progresses, it affects motor skills and causes the inability to singlehandedly perform daily tasks such as bathing, dressing, and eating. Alzheimer’s affects over 6.5 million Americans, according to the FDA.

Bradley DiTeresi, Wealth Management, Right Running Shoes

Shop